Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.88 USD
+0.89 (1.78%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRAX 50.88 +0.89(1.78%)
Will PRAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
Other News for PRAX
Praxis Precision Medicines management to meet virtually with Piper Sandler
Praxis Precision Medicines management to meet virtually with Piper Sandler
Praxis Precision Medicines initiated with bullish view at Needham
Wall Street Analysts Are Bullish on Top Healthcare Picks
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst